Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 8/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100896 | 0.99 | CHRNB4 (0.38) | CHRNB4CHRNA3HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL249200 | 0.82 | HSD17B1 (0.47) | CHRNB4CHRNA3HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL9559703 | 0.82 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL8676971 | 0.80 | — | — | |
| SCHEMBL4411533 | 0.78 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9PIK3CG | |
| SCHEMBL4411632 | 0.78 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9PIK3CG | |
| SCHEMBL4412721 | 0.78 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9PIK3CG | |
| SCHEMBL17651814 | 0.72 | HSD17B1 (0.38) | HSD17B1HSD17B2CYP3A4CYP2C9PIK3CG | |
| SCHEMBL17651780 | 0.72 | HSD17B1 (0.38) | HSD17B1HSD17B2CYP3A4CYP2C9PIK3CG | |
| SCHEMBL9559685 | 0.71 | MEN1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040912-A1 | Compounds for pdt | BIOSCIENCE TECHNOLOGY INVESTMENT HOLDINGS LIMITED (MY) | 2006-02-23 | — | — | US | claimed |
| EP-1263761-B1 | COMPOUNDS FOR PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2004-12-01 | — | — | EP | claimed |
| EP-0337601-B1 | PORPHYRINS AND MEDICAMENTS FOR CANCER TREATMENT | SCOTIA HOLDINGS PLC (GB) | 1993-05-05 | — | — | EP | claimed |
| US-7375215-B2 | tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate; photodynamic therapy of cancerous and other diseased tissues | BIOSCIENCE TECHNOLOGY INVESTMENT HOLDINGS LIMITED (MY) | 2008-05-20 | — | — | US | disclosed |
| US-20060040912-A1 | Compounds for pdt | BIOSCIENCE TECHNOLOGY INVESTMENT HOLDINGS LIMITED (MY) | 2006-02-23 | — | — | US | disclosed |
| EP-1263761-B1 | COMPOUNDS FOR PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2004-12-01 | — | — | EP | disclosed |
| EP-0337601-B1 | PORPHYRINS AND MEDICAMENTS FOR CANCER TREATMENT | SCOTIA HOLDINGS PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
| US-5162519-A | Porphyrins and cancer treatment | EFAMOL HOLDINGS PLC (GB) | 1992-11-10 | — | — | US | disclosed |
| US-4992257-A | Dihydroporphyrins and method of treating tumors | EFAMOL HOLDINGS PLC (GB) | 1991-02-12 | — | — | US | disclosed |
| EP-0337601-A1 | Porphyrins and medicaments for cancer treatment | SCOTIA HOLDINGS PLC (GB) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040912-A1 | Compounds for pdt | PPOX, DHPS, HMBS | CHRNB4 4728/4885CHRNA3 4792/4885HSD17B1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.